EUVIMEDEUVIMED entdecken
Crossref

In silico and in vitro studies of Tyr-Lys-Thr tripeptide against human lung cancer cell line (A549)

Bilge Bicak, Gizem Akman

Bratislava Medical Journal · 2024

DOI: 10.4149/bll_2024_93 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bratislava Medical Journal, 2024. Verfasst von Bilge Bicak und 1 weiteren Autor:innen. Hauptthemen laut MEDLINE: Molecular Docking Simulation, Lung Neoplasms, TOR Serine-Threonine Kinases, Oligopeptides. Die Arbeit wurde bisher 2-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: The main purpose of this study is to predict the effect of Tyr-Lys-Thr (YKT) tripeptide, recognized for its anticancer properties, on lung cancer through theoretical and experimental analyzes. BACKGROUND: Peptides are important therapeutic compounds that have been studied for many years. Among these, YKT tripeptide emerges as a significant therapeutic peptide, exhibiting cytotoxic effects on various cancer cell lines. METHODS: The study investigated the involvement of the PI3K/Akt/mTOR pathway, commonly activated in human cancer, and the pivotal role of caspases in apoptosis. The interactions of YKT tripeptide with mTOR, Akt, PI3K, caspase-3, and caspase-8 were investigated through the molecular docking method. Additionally, MTT test was used to determine the cytotoxic activity of YKT against the A549 cell line across concentrations set at 0.1, 0.25, 0.5, 1, 2.5 and 5 mg/mL for 24 and 48 h. RESULTS AND CONCLUSION: In silico docking studies were conducted with PI3K, Akt1, and mTOR, known to be active in human cancer, as well as caspase-3 and caspase-8, key enzymes in apoptosis. It was determined that YKT exhibited a robust binding tendency with each receptor. YKT tripeptide was also found to have a cytotoxic effect on human lung carcinoma cell line A549 (Tab. 5, Fig. 11, Ref. 28).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Molecular Docking SimulationLung NeoplasmsTOR Serine-Threonine KinasesOligopeptidesProto-Oncogene Proteins c-aktHumansA549 CellsAntineoplastic AgentsPhosphatidylinositol 3-KinasesApoptosisComputer SimulationCaspase 8Caspase 3Signal Transduction

Stichwörter der Autor:innen

A549MTT cytotoxicity.molecular dockingpeptide

Substanzen

TOR Serine-Threonine KinasesOligopeptidesProto-Oncogene Proteins c-aktAntineoplastic AgentsPhosphatidylinositol 3-KinasesMTOR protein, humanCaspase 8Caspase 3

Zitieren

APA

Bicak, B., & Akman, G. (2024). In silico and in vitro studies of Tyr-Lys-Thr tripeptide against human lung cancer cell line (A549). Bratislava Medical Journal. https://doi.org/10.4149/bll_2024_93

Vancouver

Bicak B, Akman G. In silico and in vitro studies of Tyr-Lys-Thr tripeptide against human lung cancer cell line (A549). Bratislava Medical Journal. 2024. doi:10.4149/bll_2024_93

BibTeX
@article{Bicak2024,
  author = {Bicak, Bilge and Akman, Gizem},
  title = {In silico and in vitro studies of Tyr-Lys-Thr tripeptide against human lung cancer cell line (A549)},
  journal = {Bratislava Medical Journal},
  year = {2024},
  doi = {10.4149/bll_2024_93}
}
Kostenlos starten →